Spasticity complicating metrizamide myelography

Temporary but considerable increase in spasticity following myelography using metrizamide at 300 mgs I/ml concentration occurred in 4 patients. In 3 of the patients the diagnosis is uncertain, but it is likely to be some form of degenerative disease involving motor pathways in two of them; the fourt...

Full description

Saved in:
Bibliographic Details
Published inNeuroradiology Vol. 27; no. 5; p. 446
Main Authors Earl, H M, Earl, C J, Kendall, B E
Format Journal Article
LanguageEnglish
Published Germany 01.01.1985
Subjects
Female
Humans
Male
Metrizamide - adverse effects
Middle Aged
Muscle Spasticity - etiology
Myelography - adverse effects
Online AccessGet more information

Cover

More Information
Summary:Temporary but considerable increase in spasticity following myelography using metrizamide at 300 mgs I/ml concentration occurred in 4 patients. In 3 of the patients the diagnosis is uncertain, but it is likely to be some form of degenerative disease involving motor pathways in two of them; the fourth case has cervical spondylotic myelopathy. The spasticity might be related to the anticholinesterase activity of metrizamide or to competitive inhibition of endogenous glucose metabolism by the deoxyglucose component of the metrizamide molecule.
ISSN:0028-3940
DOI:10.1007/BF00327613